Underserved niche Zyga focuses on minimally invasive spine solutions for facetogenic and sacroiliac joint pain, representing a targeted market with potentially high demand from patients lacking effective surgical options.

Strategic acquisitions The company has a history of being acquired by RTI Surgical and has evolved within a larger spine portfolio, suggesting channels for co-marketing, distribution partnerships, and leverageable sales synergies.

Clinical leadership With ongoing studies and milestone clinical results for the SImmetry system, there are opportunities to align with key surgeons and hospitals early in adoption cycles, benefiting from testimonial-driven adoption.

Revenue growth potential Current revenue is under one million but with a substantial funding cushion and a focused product line, there is room to pursue hospital systems and SSO contracts for standardized adoption.

Competitive landscape fit Smaller, focused spine device firms often compete with mid-market players; Zyga’s compact team and niche devices position it to target mid-sized hospitals and regional distributors seeking differentiated minimally invasive solutions.